Houston, TX – 
Infrastructure Construction Corp (OTC:CHNC)
From my desk…
It is with
great pleasure that I take a moment out of my day to write this letter to
respond and/or clarify one of the most frequent questions that our shareholders
have submitted requesting information about. Our shareholders have shown interest
in further exploring and/or understanding the portion under which we conduct our
clinical trials and our development of these projects.
Alpha
Research Institute, one of CHNC’s branches and a Houston-based research
facility, is currently active and continues to become one of the top research
centers in Houston. Several clinical trials take place in Alpha on a daily
basis, these are research studies in which people volunteer to find new
treatments and ways to improve public health problems, through procedures
monitored by doctors and health professionals bound to FDA’s guidelines.
Furthermore,
Alpha’s team is responsible for planning, setting up, and executing day-to-day
management of the contracted clinical trials. Every single study is different,
so to supply these services, our multidisciplinary team must meticulously read,
analyze, comprehend, apply and work under the rules and terms of various
protocols. These protocols act as a baseline for establishing our target
patient audience so that the results of these studies are adapted to the
specific research needs of our sponsors, guaranteeing patient safety and the
proper development of each procedure.
Our research
center has a highly professional relationship with its sponsors marked by
confidentiality, which is why we cannot answer some of the questions and
disclose certain information that could harm our company or others as most of the
guidelines belong to the intellectual property of our sponsors.
However, we
are glad to share the information we can disclose. At present, Alpha has 15
clinical trials available and open for patient recruitment. These studies
include: Children’s biological sample collection, Rheumatoid Arthritis, Active
infection (STD), Chronic Diarrhea, Adult biological sample collection, Diabetic
retinopathy, Celiac disease, Suspected infection, and five different cancer
studies (which once more we cannot name due to our confidentiality agreements),
Chronic Constipation, metabolic disease studies, and Covid-19, all under the
supervision and care of our Clinical Trials Medical Director, Dr. Deepika Deol.
Moreover, we
continue to grow and expand by recruiting more doctors (Principle
Investigators), recruitment teams, and marketing strategies, to allow for the
smooth development of the clinical trials. Alpha’s team has worked non-stop to
improve many processes and expects to acquire alliances with new sponsors in
the coming year, so as to expand its clinical trial offer and improve its relationship
with its community and patients under the direction of Dr. Harpran, Director of
Clinical Trials Recruitment.
CHNC, as a
part of the research industry, does not only benefit from its well-known
profitability and opportunities, but also works on giving back to its
community, providing the necessary tools and human talent to help develop new
technologies, treatments, and solutions to improve the quality of life of
patients around the world. It is our grain of sand that works in great synergy with
our brand’s values and mission.
Conclusively,
as usual, I would like to take this opportunity to thank our directors and
shareholders, but equally important, each and every one of our staff members
that work tirelessly to meet deadlines and innovate our products on a daily
basis to create new revenue generating centers, as well as the highest possible
return for our shareholders.
All my best,
Dante Picazo
CEO of CHNC
To learn
more visit: https://www.chnc-hdh.com/
Safe Harbor
Statement
The
information posted in this release may contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. You
can identify these statements by use of the words “may,”
“will,” “should,” “plans,” “explores,”
“expects,” “anticipates,” “continue,”
“estimate,” “projects,” “intends,” and similar
phrases. Forward-looking statements involve risks and uncertainties that could
cause actual results to differ from those projected or anticipated. These risks
and uncertainties include, but are not limited to, general economic and
business conditions, effects of geopolitical conditions, competition, changes
in technology and methods of marketing, and various other factors beyond the
company’s control.
For more
information contact us at:
info@pharmacologyuniversity.com
817/528-2475 for English
214/733-0868 for Spanish
View the original release on www.newmediawire.com